ArticleScientific reports2015
Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 113 citations in OpenAlex.
- Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.The Journal of clinical investigation · 2021Trial
- Mosquito-based malaria control through genetic, microbial and immunological innovations.Nature reviews. Microbiology · 2026Review
- Genetic diversity of the Plasmodium falciparum Pfs230 gene in four East African countries supports its potential as a malaria transmission‑blocking vaccine candidate.Malaria journal · 2026Article
- Adenoviral Vectors in Gene Therapy: A Detailed Overview.Iranian biomedical journal · 2026Review
- Article
- Article
- mosGILT antibodies interfere with Plasmodium sporogony in Anopheles gambiae.Nature communications · 2025Article
- Gene drives: an alternative approach to malaria control?Gene therapy · 2025Review
- Malaria vaccines: a new era of prevention and control.Nature reviews. Microbiology · 2024Review
- Molecular characterization, expression and in-silico analysis of fibrinogen-related protein 1 (frep1) in malaria vector Anopheles stephensi.Molecular biology reports · 2024Article
- The global transcriptome ofMicrobiology spectrum · 2023Article
- A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle.NPJ vaccines · 2023Article
- Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission.iScience · 2023Article
- Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine.NPJ vaccines · 2023Article
- Single-Chain Polymer Nanoparticles Targeting the Ookinete Stage of Malaria Parasites.ACS infectious diseases · 2023Article
- Current approaches to malaria vaccines.Current opinion in microbiology · 2022Review
- Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies.Nature communications · 2022Article
- The Virtues and Vices of Pfs230: From Vaccine Concept to Vaccine Candidate.The American journal of tropical medicine and hygiene · 2022Article
- A recombinant rabies vaccine that prevents viral shedding in rabid common vampire bats (Desmodus rotundus).PLoS neglected tropical diseases · 2022Article
- Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230.NPJ vaccines · 2022Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 4 countries.
Funding
Abstract
Malaria transmission-blocking vaccines (TBVs) target the development of Plasmodium parasites within the mosquito, with the aim of preventing malaria transmission from one infected individual to another. Different vaccine platforms, mainly protein-in-adjuvant formulations delivering the leading candidate antigens, have been developed independently and have reported varied transmission-blocking activities (TBA). Here, recombinant chimpanzee adenovirus 63, ChAd63, and modified vaccinia virus Ankara, MVA, expressing AgAPN1, Pfs230-C, Pfs25, and Pfs48/45 were generated. Antibody responses primed individually against all antigens by ChAd63 immunization in BALB/c mice were boosted by the administration of MVA expressing the same antigen. These antibodies exhibited a hierarchy of inhibitory activity against the NF54 laboratory strain of P. falciparum in Anopheles stephensi mosquitoes using the standard membrane feeding assay (SMFA), with anti-Pfs230-C and anti-Pfs25 antibodies giving complete blockade. The observed rank order of inhibition was replicated against P. falciparum African field isolates in A. gambiae in direct membrane feeding assays (DMFA). TBA achieved was IgG concentration dependent. This study provides the first head-to-head comparative analysis of leading antigens using two different parasite sources in two different vector species, and can be used to guide selection of TBVs for future clinical development using the viral-vectored delivery platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.